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Transforming growth factor-b (TGF-b) stimulates the
transcription of the a2(I) procollagen gene (COL1A2).
The intracellular mediators involved in this response
remain poorly understood. In this study, we demon-
strate that primary human skin fibroblasts express
Smads, a novel family of signaling molecules, in vitro
in the absence of TGF-b. The levels of Smad 7 mRNA
was rapidly and transiently increased by TGF-b.
Transient overexpression of Smad 3 and Smad 4, but
not Smad 1 or Smad 2, caused trans-activation of a
CAT reporter gene driven by a 772 bp segment of the
human COL1A2 promoter containing putative TGF-b
response elements. Smad stimulation of promoter
activity was ligand independent, but was further
enhanced by TGF-b. Overexpression of a phosphoryl-
ation-deficient Smad 3 mutant or wild-type Smad 7,
which lacks the carboxy-terminal phosphorylation
motif, specifically inhibited TGF-b-induced activation
of COL1A2 promoter. A CAGACA sequence shown
to be a functional Smad-binding element in the
Type I collagen is the major structural component of theextracellular matrix. Transforming growth factor-β(TGF-β) stimulates type I collagen transcription(Penttinen et al, 1988; Inagaki et al, 1994; Jimenezet al, 1994; Chung et al, 1996). Transient transfection
studies with α2(I) procollagen gene (COL1A2) promoter constructs
have localized a complex TGF-β response element called TbRE
to a region between –330 bp and –255 bp (Inagaki et al, 1994).
The functional TbRE consists of a GC-rich 59 portion and Box
B. In contrast to the detailed structural analysis of TGF-β-responsive
elements in the COL1A2 promoter, little is currently known
about the intracellular signaling mechanisms that enable TGF-β to
stimulate collagen transcription in vivo and in vitro.
TGF-β signaling in mammalian cells is mediated through inter-
actions with type I and type II TGF-β receptors. These transmem-
brane serine-threonine kinase receptors exist as independent
homodimers in the absence of ligand (Massague´, 1996). Binding
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plasminogen activator inhibitor-1 gene promoter was
found within the TGF-b-response region of the
proximal COL1A2 promoter. Gel mobility shift assays
showed protein phosphorylation-dependent binding
activity in fibroblast nuclear extracts specific for this
sequence; TGF-b treatment strongly stimulated the
formation of this DNA-protein complex. Smad was
identified as a component of the CAGACA-binding
transcription complex in TGF-b-treated fibroblasts by
antibody supershifting. These results demonstrate that
(i) Smad 3 transmits TGF-b signals from the receptor
to the COL1A2 promoter in human fibroblasts, and
is likely to play an important role in stimulation of
COL1A2 promoter activity elicited by TGF-b; (ii) in
fibroblasts, Smads appear to function as inducible
DNA-binding transcription factors; and (iii) Smad 7
may be involved in autocrine negative feedback
in the regulation of COL1A2 promoter activity by
TGF-b. Key word: Smad signaling. J Invest Dermatol
112:49–57, 1999
of TGF-β to the high-affinity type II receptor results in recruitment
of the type I receptor into a ternary signaling complex. The type
I receptor then becomes phosphorylated, enabling it to propagate
the signal to intracellular targets. Genetic screens in Drosophila,
Xenopus, and C. elegans have identified a novel class of genes whose
products function downstream from receptors for TGF-β-like
ligands, and regulate architectural patterns of development (Sekelsky
et al, 1995; Graff et al, 1996; Savage et al, 1996). Nine distinct
vertebrate homologs of these proteins, called Smads, have been
cloned to date (Hoodless et al, 1996; Chen et al, 1997a; Liu et al,
1996; Zhang et al, 1996; Topper et al, 1997). The identification of
Smad mutations in human cancers suggests a role for these genes
as tumor suppressors (Hahn et al, 1996; Eppert et al, 1996). The
Smads share conserved amino- and carboxy-terminal domains
separated by a more divergent proline-rich linker region. Smad 1
and Smad 5 signal downstream of bone morphogenetic protein,
whereas Smad 2 and its close homolog Smad 3 are thought to be
activated primarily by TGF-β and activin (Chen et al, 1996;
Hoodless et al, 1996; Liu et al, 1996; Macı´as-Silva et al, 1996;
Yingling et al, 1996; Nakao et al, 1997b). It is likely that Smads
are also involved in signaling by agonists not related to the TGF-
β superfamily (Mucsi and Goldberg, 1997). After stimulation of
cells with TGF-β, cytoplasmic Smad 2 and Smad 3 interact
transiently with the activated type I TGF-β receptor, become
phosphorylated at carboxy-terminal serine residues, and associate
with Smad 4 (Lagna et al, 1996; Macı´as-Silva et al, 1996; Zhang
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Table I. Sequences and positions of primers used in RT-PCR assays
Size of amplified
mRNA Primer sequence (59–39)a GenBank accession Position (59–39) product (bp)
Smad 2 S GGAGCAGAATACCGAAGGCA AF 68018 1322 128
AS CTTGAGCAACGCACTGAAGG 1449
Smad 6 S CAAGCCACTGGATCTGTCCGA AF035528 1800 321
AS TTGCTGAGCAGGATGCCGAAG 2120
Smad 7 S ATGCTGTGCCTTCCTCCGCT AF015261 680 494
AS CGTCCACGGCTGCTGCATAA 1173
GAPDH S TGACCACAGTCCATGCCATC 584 609
AS TACATGGCAACTGTGAGGAGG 1192
aS, sense orientation; AS, antisense orientation.
et al, 1996; Liu et al, 1997; Nakao et al, 1997; Wu et al, 1997).
The hetero-oligomeric Smad 2/3–Smad 4 complex translocates
into the nucleus, where it regulates the transcription of target genes
through as-yet poorly understood mechanisms. Recently, Smad 6,
Smad 7, and Smad 9 have been identified in endothelial and
epithelial cells. These closely related proteins form a structurally
and functionally distinct class of Smads, and act as negative effectors
of TGF-β signaling in vitro (Topper et al, 1997; Imamura et al,
1997; Nakao et al, 1997).
In this study, we investigated the role of Smad signaling in
mediating the effects of TGF-β on the transcription of the type I
collagen gene. The results indicate that Smad 3 and Smad 4 are
expressed in primary human fibroblasts, trans-activate the COL1A2
promoter in vitro, and show inducible DNA-binding activity specific
for a TGF-β-response element of the COL1A2 promoter. Smad
7, whose expression in fibroblasts is rapidly induced by TGF-β,
abrogates ligand-induced stimulation of collagen promoter activity,
and may play a role in an intracellular negative feedback loop for
TGF-β signaling.
MATERIALS AND METHODS
Fibroblast cultures Primary cell cultures were established from neonatal
foreskin biopsies by previously described explant techniques (Varga et al,
1987), and COS cells were from ATCC. Media were obtained from
Biowhittaker (Walkersville, MD); all other tissue culture reagents were
from Gibco BRL (Grand Island, NY). Cells were grown at 37°C in a 5%
CO2 atmosphere in Dulbecco’s (COS cells) or modified Eagle’s medium
supplemented with 10% fetal calf serum, 1% vitamins, 1% penicillin/
streptomycin, and 2 mM L-glutamine, and studied between passages 4–8.
When the cells reached confluence, fresh medium with varying concentra-
tions of fetal calf serum with or without TGF-β2 (from Celtrix, Santa
Clara, CA), or TGF-β1 (from Amgen, Thousand Oaks, CA) was added,
and cultures were harvested following a further 24–48 h incubation.
Extraction and analysis of RNA At the end of each experiment, total
RNA was isolated from fibroblasts maintained in medium with 1% fetal
calf serum using TRIZOL Reagent (Gibco BRL). Relative levels of
mRNA were examined by northern analysis with [α-32P]dCTP-labeled
cDNA probes. Following washing of the nylon membranes, the cDNA-
mRNA hybrids were visualized by autoradiography on Kodak X-AR5
films exposed for 24–72 h with intensifying screens. The following cDNA
probes were used: glyceraldehyde-3-phosphate dehydrogenase (GAPDH),
a 1.4 kb restriction fragment including the entire coding region of Smad
3, and a 1.6 kb restriction fragment including the entire coding region of
Smad 4 (Zhang et al, 1996).
Coupled reverse transcription-polymerase chain reaction (RT-
PCR) assay To examine the expression of Smad 2, Smad 6, and Smad
7 mRNA in fibroblasts, a coupled RT-PCR assay was employed. At the
end of the indicated periods of incubation with or without TGF-β1, total
RNA was extracted from confluent fibroblasts, as described for northern
analysis. Samples were treated with RNase-free DNase according to the
manufacturer’s instructions (Promega, Madison, WI) to remove potentially
contaminating DNA. One microgram of RNA was then copied into
cDNA in 12 µl reaction mixture using the SuperScript Preamplification
System for first-strand cDNA synthesis kit (Gibco BRL). Aliquots of the
resulting cDNA were then subjected to PCR amplification in the presence
of 1 unit of AmpliTaq polymerase (Perkin-Elmer, Norwalk, CT), 15 µM
of each primer, 200 µM dNTP, 1.5 mM MgCl2, 10 Ci [α-32P] dCTP,
and 2.5 µl PCR Buffer (Perkin-Elmer) in a total volume of 25 µl.
Oligonucleotide primers specific for Smad 2, Smad 6, and Smad 7 cDNA
shown in Table I were designed using ‘‘Primer Design’’ software (Scientific
and Educational Software, Durham, NC). The reaction was incubated at
94°C for 30 s and at 72°C for 30 s, stopped at 72°C for 5 min, and cooled
on ice. At the end of the amplification, the size of the PCR products
was determined by comparison with standard DNA markers, using 8%
polyacrylamide gel electrophoresis and ethidium bromide staining. In other
experiments, 9 µl of each reaction was taken at different amplification
cycles, and analyzed by electrophoresis. The gels were then dried and
exposed to Kodak X-ray film for 5 min. The segments of the gel
corresponding to the bands detected by autoradiography were excised, and
the amount of radioactivity was determined by liquid scintillation counting.
As positive controls, duplicate samples of cDNA were amplified in parallel
with GAPDH-specific primers, and analyzed as described above. As
negative control, cDNA synthesis without RT was performed to exclude
PCR contamination. Experiments were repeated three times.
Transient transfections For transient transfection experiments, the
p3TP-lux, plasminogen activator inhibitor-1 (PAI-1)-CAT, COL1A2-CAT,
and pSV0CAT constructs were used as reporters. The p3TP construct
contains three concatamerized repeats of the AP-1 site of the collagenase
promoter, and the TGF-β response element of the PAI-1 promoter; the
PAI-1-CAT chimeric construct contains sequences from –1237 to 120 bp
of the rat PAI-1 promoter fused to the CAT reporter gene (Bruzdzinski
et al, 1993); the COL1A2-CAT construct contains sequences from –772
to 158 bp of the human COL1A2 promoter fused to the CAT reporter
gene (Ihn et al, 1997); and pSV0CAT is a negative control plasmid.
Fibroblasts were grown to 70% confluence in 60 mm dishes. The media
were changed, and 4 h later cultures were transfected with the reporter
plasmids (20 µg), along with the indicated wild-type or mutant expression
plasmids or corresponding empty constructs (1 µg), employing the calcium-
phosphate/DNA coprecipitation method. Expression vectors for human
Smad 1 and Smad 2 (gifts from L. Attisano, University of Toronto,
Toronto) contain in-frame amino-terminal FLAG epitope tag (Eppert et al,
1996; Hoodless et al, 1996). Expression vectors for Smad 4 (from R.
Derynck, University of California, San Francisco), and Smad 3 and Smad
3A, which carries three carboxy-terminal serine-to-alanine substitutions
(from H. Lodish, Whitehead Institute), contain the FLAG epitope tag at
the amino-terminal domain (Zhang et al, 1996; Liu et al, 1997). Expression
vector for Smad 7 (from P. ten Dijke, Ludwig Institute for Cancer
Research) was constructed by subcloning a Smad 7 cDNA in the pcDNA3
expression vector (Nakao et al, 1997). Expression vector for Smad 6 (from
M. Kawabata, Japanese Foundation for Cancer Research) contains a FLAG
epitope in the amino terminal domain in pcDNA3 (Imamura et al, 1997).
Expression vector for Smad 9 (from T. Watanabe, Otsuka Pharmaceuticals)
was constructed by subcloning a Smad 9 cDNA in the pT7Blue expression
vector (Watanabe et al, 1997). A Smad 2 mutant expression vector (from
H. Goldberg, Hospital for Sick Children) was constructed by subcloning
a Smad 2 cDNA with a premature stop codon in the pcDNA3 expression
vector (Mucsi and Goldberg, 1997). In order to control for minor variations
in transfection efficiency, 50 ng renilla luciferase DNA (Promega), which
expresses luciferase under the control of the cytomegalovirus promoter,
was included in all transfections. Fresh media containing 0.1% fetal calf
serum and TGF-β1 or TGF-β2 (12.5 ng per ml) were then added, and
the cells were harvested 48 h after transfection. The total protein content
of the extracts was quantitated by the Bradford Coomassie Blue G binding
assay (Bradford, 1976) (Bio-Rad Laboratories, Richmond, CA). Identical
amounts of protein from each cell extract (30 µg per assay) were used for
parallel determination of CAT activity. CAT activity was determined by
an organic solvent extraction assay using [14C] chloramphenicol and
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butyryl-CoA at assay conditions predetermined to be within the linear
range for CAT activities of the samples. Radioactive acetylated chloram-
phenicol was quantitated by liquid scintillation counting. Luciferase activity
was determined using the Dual-Luciferase Reporter Assay System
(Promega).
Preparation of nuclear extracts and electrophoretic gel mobility
shift assay Fresh media with or without TGF-β1 (12.5 ng per ml) were
added to confluent fibroblasts. At the end of the indicated incubation
periods, nuclear extracts were prepared as described (Andrews and Faller,
1991), and protein concentrations were determined by the Bio-Rad assay.
Glutathione-S-transferase (GST)-Smad 3 MH1-domain fusion protein
vectors (Zawel et al, 1998) were expressed in Escherichia coli and partially
purified by chromatography on glutathione-Sepharose 4B columns
(Pharmacia, Piscataway, NJ). Double-stranded oligonucleotides correspond-
ing to a 24 bp sequence spanning –272 to –249 bp of the COL1A2
promoter (COL1A2-CAGA, 59-GGAGGTATGCAGACAACGAGT-
CAG-39) harboring the CAGACA motif, a 24 bp sequence spanning
–386 to –363 bp of the COL1A2 promoter (COL1A2–386/–363, 59-
CTAGCGGCCTCTAGACGTTTAAGA-39) harboring a CAGA motif,
or a 26 bp sequence [Smad binding element (SBE), 59-GGAGTATGT-
CTAGACTGA-CAATGTAC-39] harboring a consensus palindromic
Smad-binding element (Zawel et al, 1998) were generated. Additional
probes were prepared by introducing subsitution mutations (underlined) in
the –272 to –249 COL1A2 sequence: COL1A2-CAGA-m2,
59-GGAGGTATGACTACAACGAGTCAG-39; COL1A2-CAGA-m3,
59-GGAGGTAT-GCAGCACACGAGTCAG-39; COL1A2-CAGA-m4,
59-GGAGGTATGCAGACACAT-AGTCAG-39; and COL1A2-CAGA-
m5, 59-GGAGGTATGACTCACACGAGTCAG-39. The probes were
end-labeled with [γ-32P]ATP using T4 polynucleotide kinase, or with
[α-32P]dATP using Klenow fragment of DNA polymerase I for the
phosphatase studies. Electrophoretic gel mobility shift assays were performed
in binding reactions (total volume 20 µl) containing 2 µg of double-
stranded poly[d(I-C)], 3–10 µg nuclear extract or 1 µg of recombinant
Smad 3, and 100,000 cpm of radiolabeled probes (µ0.2–0.5 ng). In order
to establish the specificity of the protein-DNA complexes, unlabeled
oligonucleotide competitors in 2–50-fold molar excess were added in the
binding reactions 5 min before the labeled probes. Polyclonal SED
antibodies (1–10 µl, as indicated) to Smad 2/3 (Nakao et al, 1997), or pan-
FOS antibodies, which react with all members of the FOS family (Santa
Cruz Biotechnology, SC-235X), or preimmune serum were added to the
binding reactions 15 min prior to the probes. Following incubation of the
reaction mixtures on ice for 30 min, protein-DNA complexes were
resolved from free probes in nondenaturing 5.5% polyacrylamide gels using
low ionic strength buffers. The gels were then dried under vacuum and
exposed to X-ray film at –70°C. To examine the effect of in vitro
dephosphorylation on DNA-binding activity, nuclear extracts were incub-
ated with 0.8 units per g protein calf intestinal alkaline phosphatase (MBI
Figure 1. Expression of Smad mRNA and protein in human dermal
fibroblasts. (A) Northern analysis. Total RNA was isolated from confluent
fibroblasts and analyzed by northern hybridization with a Smad 3
cDNA. The membranes were then stripped, and re-hybridized to Smad 4
and GAPDH cDNA. A representative autoradiogram is shown. (B)
Demonstration of Smad expression in fibroblasts by coupled RT-PCR.
Primers specific for Smad 2, Smad 6, Smad 7, or GAPDH, described in
Table I, were used to amplify cDNA from confluent fibroblasts by PCR.
Amplification products in the linear range for Smads and GAPDH were
electrophoresed and visualized under UV light. Representative results are
shown. (C, D) Rapid induction of Smad 7 mRNA expression by TGF-
β. RNA was prepared from confluent fibroblasts, and Smad 7 and GAPDH
mRNA levels were determined by coupled RT-PCR in the presence of
[α-32P]dCTP. (C) Fibroblasts were treated with TGF-β1 for varying
periods up to 24 h as indicated. C, fibroblasts incubated for 24 h in
medium only. A representative autoradiogram is shown. (D) At the
indicated number of PCR cycles, equal aliquots from the control (0),
90 min TGF-β-treated, and 24 h untreated samples were taken for
electrophoresis, and the amplification products were visualized by
autoradiography. The cpm incorporated in each band was determined by
scintillation counting. The values shown are normalized for coamplified
GAPDH. (E) Western immunoblot analysis of Smad 2/Smad 3. Nuclear
extracts from untreated fibroblasts (lane 1) or fibroblasts treated with TGF-
β1 (lane 2) were subjected to SDS-polyacrylamide gel electrophoresis and
immunoblot analysis, as described in Materials and Methods. A representative
chemiluminogram is shown. Arrows indicate the relative migration of Smad
2 and Smad 3. Molecular mass markers in kDa are shown.
Fermentas, Amherst, NY) at room temperature for 30 min, followed by
the phophatase inhibitor sodium orthovanadate (Sigma, St. Louis, MO),
and then examined by gel shift assays with Klenow-labeled DNA probes,
as described above.
Immunoblotting and western analysis In order to detect endogenous
Smad proteins, nuclear extracts from confluent fibroblasts incubated with
TGF-β1 or left untreated for 48 h were prepared, and boiled at 90°C
with sample buffer for 5 min. Extracts (15–30 µg) were subjected to
electrophoresis in 7% SDS polyacrylamide gels in a minigel apparatus for
1 h. The proteins were then trans-blotted onto nitrocellulose membranes
for 30 min at 15 V. After blocking with 5% milk, the membranes were
incubated with primary antibodies or preimmune serum for 1 h, followed
by biotinylated goat anti-rabbit IgG secondary antibodies for 1 h, and
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washed with Tris-saline buffer. The SED anti-Smad antibody recognizes
Smad 2 and Smad 3. Secondary antibodies were detected by incubation
with avidin-biotinylated horseradish peroxidase macromolecular complex
(Vector Laboratories, Burlingame, CA) for 1 h, and detected by incubation
with super-signal chemiluminescent HRP substrate (Pierces, Rockford, IL)
for 3 min, followed by exposure to X-ray film for 1 s to 3 min. Molecular
standards (Bio-Rad Laboratories, Hercules, CA) were also electrophoresed.
In order to detect protein expression from transiently transfected Smads,
COS-7 cells were transfected with Smad expression vectors, and harvested
following a 48 h incubation. Proteins from the transfected cell lysates were
resolved by 10% SDS-polyacrylamide gel electrophoresis, and probed with
the anti-FLAG M2 antibody (Kodak, New Haven, CT), and detected by
ECL system (Amersham, Arlington Heights, IL).
RESULTS
Expression of endogenous Smad in primary human
fibroblasts The pathway-restricted Smad 2 and Smad 3, and
their shared signaling partner Smad 4, have been shown to be
broadly expressed in mammalian tissues, and in established epithelial
and osteoblastic cell lines (Nakao et al, 1997a, b; Yamamoto et al,
1997; Yang et al, 1998). We were interested in determining if
primary fibroblasts, which are less likely to contain mutations
in TGF-β signaling proteins than established cell lines, showed
expression of these Smads. Total RNA was isolated from low-
passage confluent human skin fibroblasts and examined by northern
analysis. Two distinct Smad 3 mRNA transcripts, with approximate
sizes of 3.0 and 7.0 kb, and two Smad 4 mRNA transcripts (4.0
and 9.5 kb) were detected (Fig 1A). In agreement with previous
findings in mouse embryos, the 4.0 kb Smad 4 transcript was the
major form (Yang et al, 1998). These results were consistent
in four independent experiments with fibroblasts from different
individuals, and in media with 1% fetal calf serum or no serum. In
order to detect low abundance Smad mRNA expression, a coupled
RT-PCR reaction was used. Amplification products of the predicted
128 bp, 321 bp, or 494 bp size, corresponding to Smad 2, Smad
6, and Smad 7 mRNA, could be detected in unstimulated fibroblasts
(Fig 1B). The relative amount of the Smad 7 mRNA was increased
rapidly and transiently in fibroblasts treated with TGF-β1 (12.5 ng
per ml), whereas mRNA levels for Smad 2, Smad 6, and GAPDH
remained unchanged (Fig 1C, D, and data not shown).
Immunoblotting with the cross-reactive SED anti-Smad antibody
indicated that Smad 2/Smad 3 protein could be detected in
fibroblast nuclear extracts in the absence of added TGF-β. The
levels of Smad 2/3 were not consistently altered by treatment of
the fibroblasts with TGF-β (Fig 1E).
Overexpression of wild-type or mutant Smads In order to
examine the regulation of TGF-β-responsive genes in primary
fibroblasts, transient transfections were employed. First, the regula-
Figure 2. Overexpression of Smad 3 or Smad 4 trans-activates
COL1A2, whereas mutant Smad 3 abrogates stimulation. (A) Ligand-
independent activation of reporter constructs. p3TP-lux (3 µg) and PAI-1-
CAT (20 µg) (left and right panels) were transfected into fibroblasts along
with the indicated Smads, as described in Materials and Methods. CAT and
luciferase activities were determined following a 48 h incubation, and
corrected for minor variations in transfection efficiencies by renilla luciferase.
The results, expressed as -fold increase in CAT or luciferase activity induced
by Smad compared with the activity of the reporter in the presence of the
empty vector (set to 1), represent the mean 6 SEM of four determinations.
Note the difference in scales between the left and right panels. (B) Stimulation
of COL1A2-CAT by Smads. The COL1A2-CAT, used as the reporter,
was cotransfected with the indicated Smads alone, or in combination. Inset,
western blot of COS-7 cells transfected with the indicated Smad-FLAG
expression constructs, and probed with anti-FLAG antibodies. V, vector
only. (C) Inhibition of Smad signaling by mutant Smad 3. Fibroblasts were
transfected with the indicated wild-type Smads, phosphorylation-deficient
Smad 3 (Smad 3A), or Smad 2 (mSmad 2) mutants, or the empty
vector along with COL1A2-CAT. CAT activity was determined following
treatment of the fibroblasts with TGF-β1 for 24 h. The results shown
represent the mean of at least two independent experiments in duplicates.
u, Untreated fibroblasts; j, TGF-β-treated fibroblasts.
tion of the 3TP promoter, a well-characterized artificial construct
that is a sensitive indicator of TGF-β-dependent transcriptional
responses in mammalian cells (Keeton et al, 1991), was examined.
In agreement with results from earlier studies with immortalized
Mv1Lu and SW480.7 cells, the activity of the 3TP promoter was
substantially induced in the fibroblasts cotransfected with Smad 3
(Fig 2A, left panel). This activation was further enhanced in the
presence of TGF-β (data not shown). Smad 4 caused only a modest
(50%) stimulation of 3TP promoter activity. Similar effects were
obtained with PAI-1-CAT as the reporter (Fig 2A, right panel), but
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the response of the p3TP construct to Smad was substantially
greater than that of PAI-1. This is consistent with previous reports,
and probably reflects the presence of additional enhancer sequences
in the 3TP promoter (de Winter et al, 1997). CAT activity driven
by the negative control plasmid pSV0CAT was not stimulated by
Smads or by TGF-β.
Next, equal amounts of Smad 1, Smad 2, Smad 3, or Smad 4,
all under CMV promoter regulation, were transiently transfected
into confluent fibroblasts along with the COL1A2-CAT construct,
which contains 772 bp of the promoter including the putative
TGF-β response elements. Smad 3 by itself caused a 6–9-fold
increase in COL1A2 promoter activity compared with fibroblasts
transfected with empty vector (Fig 2B). Smad 4 caused a similar
though less marked stimulation. In contrast, neither bone morpho-
genetic protein-specific Smad 1, nor TGF-β/activin-specific Smad
2 had an effect on promoter activity. Furthermore, in contrast to
previous studies (Liu et al, 1997; Nakao et al, 1997), combinations
of Smad 2, Smad 3, and Smad 4 did not consistently result in an
additive effect. The expression of each Smad protein in the
transfected COS cells was comparable (Fig 2B, upper panel). Next,
the effect on TGF-β on Smad-regulated COL1A2 activity was
examined. The results indicated that addition of TGF-β to the
cultures caused a further increase in stimulation of COL1A2
promoter activity induced by Smad 3 (Fig 2C). These results were
identical whether TGF-β1 or TGF-β2 was used (data not shown).
To investigate the functional role of individual Smads in mediat-
ing the effects of TGF-β on COL1A2 promoter activity in
fibroblasts, loss-of-function experiments were performed. In Smad
3, replacement of three carboxy-terminal serine residues corres-
ponding to amino acids 422, 423, and 425 with alanine interferes
with phosphorylation of the protein by the activated TGF-β
type I receptor (Liu et al, 1997). As shown in Fig 2(C), this
phosphorylation-deficient Smad 3 mutant almost fully blocked the
stimulation of COL1A2 activity by TGF-β. In contrast, a truncated
form of Smad 2 lacking the 44 carboxy-terminal amino acids did
not prevent stimulation of the promoter, indicating the specificity
of the inhibitory effect, and suggesting that in fibroblasts, Smad 3,
but not Smad 2, was involved in transducing the signal from
TGF-β receptors to the COL1A2 promoter.
Smad 6, Smad 7, and Smad 9 are distinct members of the Smad
family. Transient overexpression in the fibroblasts of Smad 7, but
not Smad 6 or Smad 9, reduced by 45% the basal activity of
COL1A2 in the presence of the empty vector, and significantly
abrogated its induction by TGF-β (Fig 3). Because the expression
of Smad 7 mRNA is induced by TGF-β (Fig 1), it is likely that
Smad 7 functions as an autocrine negative regulator of TGF-β
signaling in fibroblasts.
Smad DNA-binding activity TGF-β has been shown to stimu-
late the translocation of Smad 2 and Smad 3 from the cytoplasm
into the nucleus, but the precise nuclear function of these Smads
has not been established. In order to examine if endogenous
fibroblast Smads could modulate transcription directly by binding
to DNA sequences in target genes, gel mobility shift assays
were performed. Nuclear extracts were prepared from confluent
fibroblasts left untreated, or incubated with TGF-β1. Synthetic
double-stranded oligonucleotides spanning from –272 to –249 bp
of the COL1A2 promoter were prepared and used as probes. This
region of the COL1A2 promoter contains a CAGACA sequence
that was shown to be a functional Smad-binding element in the
human PAI-1 promoter (Dennler et al, 1998) Furthermore, the
CAGACA sequence lies within Box B of a previously identified
complex TGF-β response element of COL1A2 (Inagaki et al,
1994). The results showed that nuclear extracts from untreated
fibroblasts generated a DNA-protein complex with the –272/–249
COL1A2-CAGA probe, or with a consensus SBE probe (Fig 4A).
Identical pattern of band shift was observed with nuclear extracts
prepared from different fibroblast lines in three independent experi-
ments (data not shown). Treatment of the fibroblasts with TGF-
β1 caused a rapid and transient increase in the formation of the
Figure 3. Smad 7 abrogates stimulation of COL1A2 by TGF-b.
Smad 6, Smad 7, Smad 9, or empty vector (1 µg) were transfected into
fibroblasts along with COL1A2-CAT (20 µg), as described in Materials and
Methods. TGF-β1 was added to the cultures, and CAT and luciferase
activities were determined following a 24 h incubation, and corrected for
minor variations in transfection efficiencies by renilla luciferase. The results,
expressed as -fold increase in CAT or luciferase activity induced by Smad
compared with activity of the reporter in the presence of the control
vector (set to 1), represent the mean 6 SEM from three independent
experiments. u, Untreated fibroblasts; j, TGF-β-treated fibroblasts.
DNA-protein complex (Fig 4A). Competition with molar excesses
of homologous COL1A2-CAGA, SBE, or COL1A2–386/–363
probes, or unrelated AP-1-binding oligonucleotides, established
the specificity of this DNA-protein complex (Fig 4B). Specificity
was further supported by the reduction of endogenous transcription
factor binding to mutated COL1A2-CAGA probes (Fig 4C).
In order to identify the trans-acting factors participating in the
transcription complex assembled on the CAGACA sequence of
COL1A2, supershift assays with antibodies were performed. The
polyclonal SED antibody, which cross-reacts with Smad 2 and
Smad 3 (Nakao et al, 1997), caused a supershift, confirming that
the DNA-protein complex generated with nuclear extracts from
TGF-β-treated fibroblasts included a pathway-restricted Smad
(Fig 4D). In the presence of excess antibody (10 µl), the DNA-
protein complex was completely supershifted, and the residual
binding was fully eliminated (data not shown). Pan-FOS antibodies
or preimmune serum failed to cause a supershift. Taken together,
these results indicate that a transcription complex including Smad
or related proteins in nuclear extracts from TGF-β-treated
fibroblasts binds directly and specifically to COL1A2 promoter
sequences homologous to a Smad recognition site in the PAI-1
promoter, and previously implicated in TGF-β responsiveness
(Inagaki et al, 1994). To determine if DNA binding of the
endogenous Smad-containing transcription complex was phos-
phorylation dependent, nuclear extracts were subjected to in vitro
dephosphorylation. As shown in Fig 4(E), in vitro calf intestinal
alkaline phosphatase treatment of nuclear extracts prepared from
TGF-β-treated fibroblasts resulted in a loss of binding to the
CAGACA Smad-binding sequence. In order to define the core
sequence required for optimal Smad DNA binding, mutated CAGA
probes were used in gel shift assays with bacterially expressed GST-
Smad 3 MH1 domain fusion proteins. The results, shown in Fig 5,
indicated that the integrity of the CAGACA core sequence was
essential for efficient binding of recombinant Smad 3.
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Figure 4. Endogenous Smads display sequence-specific inducible DNA-binding activity. A 24 bp oligonucleotide corresponding to the human
COL1A2 promoter sequences between –272 and –249 bp (COL1A2-CAGA), a 26 bp oligonuclotide containing a consensus SBE, and a 24 bp
oligonucleotide corresponding to the human COL1A2 promoter sequences between –386 and –363 bp (COL1A2–386/–363) were synthesized.
Radiolabeled oligonucleotides were then used as probes in gel mobility shift assays, as described in the Materials and Methods. Unlabeled oligonucleotides
were used as competitors. (A) Inducible DNA-binding activity. The SBE (lanes 1–5) and the COL1A2-CAGA (lanes 6–10) oligonucleotides were used
as probes. The nuclear extracts were as follows: lanes 2, 6, untreated fibroblasts; lanes 3–5 and 7–9, fibroblasts treated with TGF-β1 for 5–240 min, as
indicated on top; lanes 1, 10, no protein. (B) Competition assay. Nuclear extracts were prepared from fibroblasts treated with TGF-β for 15 min, and
incubated with the radiolabeled COL1A2-CAGA probe. Lane 1, no competitor DNA; lanes 2–4, 100-, 20-, or 4-fold molar excesses of unlabeled
homologous COL1A2-CAGA oligonucleotide; lanes 5–7, 100-, 20-, or 4-fold molar excesses of unlabeled COL1A2–386/–363 oligonucleotide; lanes 8–
10, 100-, 20-, or 4-fold molar excesses of unlabeled consensus SBE oligonucleotide; lanes 11, 12, 100- or 20-fold molar excesses of unlabeled AP-1
consensus binding site oligonucleotide. (C) Binding to nuclear extract prepared from fibroblasts treated with TGF-β1 for 15 min to the indicated mutated
COL1A2-CAGA probes (described in Materials and Methods). (D) Antibody supershifting. Nuclear extracts from fibroblasts treated with TGF-β1 for
15 min were preincubated without antibodies (lane 2), SED anti-Smad 2/Smad 3 antibodies (2 or 4 µl as indicated, lanes 3, 4), or 2 or 4 µl of pan-FOS
antibodies (lanes 6, 7) or preimmune serum (lane 5) for 30 min prior to binding reaction. The COL1A2-CAGA oligonucleotide probe was Klenow-
labeled and incubated with 10 µg nuclear extract, and free probe was separated from DNA-protein complexes by electrophoresis. The shifted (arrowhead)
and supershifted (arrow) bands are indicated on the right side of the autoradiogram. Lane 1, free probe. (E) Modulation of nuclear extract DNA-binding
activity by in vitro dephosphorylation. Nuclear extract prepared from fibroblasts treated with TGF-β for 60 min were pretreated with calf intestinal alkaline
phosphatase for 30 min, followed by sodium orthovanadate (1 mM). Lane 1, no calf intestinal alkaline phosphatase; lane 2, calf intestinal alkaline
phosphatase; lane 3, free probe.
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Figure 5. Recombinant Smad 3 binding requires the CAGACA
sequence. COL1A2-CAGA oligonucleotides carrying mutations
(described in Materials and Methods) were used as probes in gel shift assays
with bacterially expressed GST-Smad 3 MH1 domain fusion proteins. A
representative autoradiogram is shown.
DISCUSSION
TGF-β stimulates the transcription of collagen and other genes
coding for extracellular matrix proteins in vitro and in vivo, and
plays a central role in tissue repair and pathologic fibrosis (Varga
and Jimenez, 1995). Although the cis-acting DNA elements mediat-
ing the activation of target gene expression in response to TGF-β
have been extensively investigated, the intracellular signaling mole-
cules that couple the activated TGF-β receptor to the nucleus have
remained largely unknown. The recent identification of the Smad
protein family has provided novel insights regarding TGF-β sig-
naling. In this study, we explored whether Smad proteins play a
role in activation of collagen transcription in human fibroblasts. The
expression of specific Smad moieties appears to widely distributed in
different tissues, but so far little is known about their cell lineage-
specific expression. These results indicate that Smad 2, Smad 3,
and Smad 4, as well as Smad 6 and Smad 7 mRNA, are detectable
in cultured fibroblasts in the absence of TGF-β. Northern analysis
indicated the presence of two distinct mRNA transcripts for Smad
3 as well as for Smad 4. The size of the transcripts is consistent
with previous reports from cancer cell lines and embryonic tissues
(Nakao et al, 1997; Zhou et al, 1998). Whether the existence of
multiple Smad mRNA transcripts indicates alternative splicing or
several polyadenylation sites remains to be determined. Smad 2/
Smad 3 protein was detected in the nucleus of unstimulated
fibroblasts, and its levels were not appreciably changed by exposure
of the fibroblasts to TGF-β. Constitutive ligand-independent
nuclear localization of the pathway-restricted Smads has been
previously described (Moustakas and Kardassis, 1998).
We show that transient overexpression in fibroblasts of Smad 3,
and to a lesser degree Smad 4, stimulated activity of a proximal
COL1A2 promoter segment that contains putative TGF-β response
elements of the gene (Inagaki et al, 1994; Chung et al, 1996), in
the absence TGF-β. Trans-activation of COL1A2 was specific for
Smad 3 and Smad 4, because overexpression of Smad 1, which is
implicated in bone morphogenetic protein signaling, failed to
stimulate transcription. Surprisingly, the TGF-β/activin-restricted
Smad 2 was also unable to trans-activate the promoter. Smad 2 has
a 92% amino acid sequence similarity to Smad 3 (Zhang et al,
1996), differing only by the presence of two stretches of amino
acids in the MH1 domain, and has been considered to be redundant
with Smad 3 in TGF-β signaling (Hu et al, 1998). Significant
functional differences between Smad 2 and Smad 3, however, were
recently demonstrated on the transcription of the PAI-1, p21, and
goosecoid genes (Dennler et al, 1998; Labbe et al, 1998; Moustakas
and Kardassis, 1998), and are likely to be due to their differential
ability to bind to DNA (Zawel et al, 1998). Taken together with
these findings, these results suggest that Smad 2 and Smad 3 may
have different subsets of target genes and different functional roles
in transcriptional regulation; however, we cannot exclude the
possibility that Smad 2 also plays a role in mediating the effect of
TGF-β on COL1A2 activity. In contrast to previous reports
showing that Smad 3 synergizes with Smad 2 and Smad 4 to
stimulate the transcription of TGF-β responsive genes (Nakao et al,
1997), we were not able to demonstrate synergistic interactions
among the Smads in fibroblasts. Further studies will be necessary
to delineate the functional relationship between Smad 2 and Smad
3 in mediating TGF-β signals to the COL1A2 promoter. The
ligand-independent activation of target gene transcription by Smad
3 and Smad 4 suggests that they may function as intracellular
mediators of TGF-β signaling in fibroblasts.
The highly conserved carboxy-terminal domain has been shown
to play a critical role in the signaling function of the pathway-
restricted Smads (Lagna et al, 1996; Liu et al, 1997; Wu et al, 1997).
Because phosphorylation and multimeric complex formation are
considered to be important for nuclear translocation and transcrip-
tional activation by Smads, mutations or loss of the serine residues
results in interruption of Smad signaling. In these experiments, a
Smad 3A mutant harboring substitutions that replace critical serine
residues with alanine (Liu et al, 1997) abrogated the stimulation of
COL1A2 promoter activity by TGF-β. In contrast, a phosphoryl-
ation-deficient mutant of Smad 2 (Mucsi and Goldberg, 1997)
failed to inhibit TGF-β signaling. These findings further implicate
Smad 3 as an important component of Smad signaling, and point
to hitherto unappreciated functional differences between Smad 2
and Smad 3.
Transient overexpression of Smad 7, but not Smad 6 or Smad
9, efficiently blocked the stimulation of COL1A2 promoter activity
by TGF-β in the fibroblasts. The ‘‘anti-Smads’’ lack the amino-
terminal domain and carboxy-terminal SSXS phosphorylation
sequences that are conserved among the pathway-restricted Smads.
The interaction of Smad 7 with the activated TGF-β type I
receptor is thought to result in the formation of a stable complex,
which in turn blocks the phosphorylation of Smad 2 and Smad 3
by the receptor, thus interrupting ligand-induced signaling via the
pathway-restricted Smads and downregulating the sensitivity of the
cell to TGF-β (Hayashi et al, 1997; Nakao et al, 1997; Ishisaki et al,
1998). Whether Smad 7 abrogates TGF-β stimulation of COL1A2
promoter activity by interfering with activation of Smad 3, or via
competetive inhibition of its association with Smad 4 or coactivators,
remains to be determined (Hu et al, 1998). Smad 6 blocks bone
morphogenetic protein-induced Smad signaling by forming a
complex with Smad 1, but not with the TGF-β-specific Smads,
thus acting as a ‘‘decoy’’ via competition for the obligate signaling
partner Smad 4 (Hata et al, 1998). In these studies, overexpression
of Smad 6 did not block the stimulation of COL1A2 promoter
activity by TGF-β, indicating ligand-specific differences in the
functional roles of the anti-Smads.
The expression of Smad 7 mRNA in the fibroblasts was rapidly
and transiently induced by TGF-β. These results indicate that Smad
7 is a novel and relatively early response gene for TGF-β. Smad 7
may function as an autocrine negative regulator of COL1A2
transactivation by TGF-β in a manner reminescent of other
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cytokine-inducible autoregulatory switch-off signals that are likely
to have important physiologic roles in limiting the duration or
intensity of the cytokine-induced response. A failure of the Smad
7-mediated endogenous inhibitory feedback loop could lead to
unchecked activation of the intracellular TGF-β signaling cascade,
resulting in constitutive activation of COL1A2 transcription follow-
ing a transient exposure of the fibroblasts to TGF-β.
The mechanisms of target gene activation by Smads are not well
understood. Recent evidence indicates that Smad proteins can
interact with DNA. In Xenopus, Smad forms a heterodimer with
the winged-helix DNA-binding protein forkhead activin signal
transducer FAST-1 (Chen et al, 1997b). In contrast, in Drosophila,
the amino-terminal domain of Mad, though not the full-length
protein, can bind directly to decapentaplegic-responsive elements
within the vestigial gene promoter (Kim et al, 1997). Full-length
human Smad 4 was shown to bind directly to DNA in the artificial
3TP promoter; however, the putative Smad-binding sequence was
dispensable for TGF-β-dependent activation of this promoter,
raising doubts about the functional significance of this binding
(Yingling et al, 1997). Recently, a palindromic sequence (SBE)
binding to bacterially expressed GST-Smad 3 MH1 domain and
Smad 4 full-length fusion proteins, was identified using a PCR
selection strategy (Zawel et al, 1998). The sequence contains the
CAGA motif, which is also found in the Smad-binding element
of the PAI-1 promoter (Dennler et al, 1998). In these studies, we
demonstrate that endogenous transcription factors in nuclear extracts
from both untreated and TGF-β-treated fibroblasts, as well as
bacterially expressed GST-Smad 3 MH1 domain fusion protein,
bound specifically to a COL1A2 promoter region containing the
CAGACA motif and displaying strong homology to the PAI-1
Smad-binding element. Remarkably, this newly identified Smad-
binding element lies within a region of the COL1A2 promoter
previously implicated in TGF-β responsiveness of the gene (Inagaki
et al, 1994). Although these observations strongly suggest that Smad
binding to the –272 to –249 bp region mediates activation of the
COL1A2 promoter in response to TGF-β, the functional role of
this region must be confirmed with additional studies. Furthermore,
it remains to be established whether in vivo, additional nuclear
factors might also be required for the formation of the transcrip-
tionally active complex. The close proximity of several Sp1 binding
sites to the Smad-binding CAGACA sequence in the COL1A2
promoter is significant, raising the possibility that stimulation
of COL1A2 transcription by TGF-β may involve synergistic
interactions among Smad and Sp1, as has been shown in the case
of p21 promoter regulation (Moustakas and Kardassis, 1998).
The transcription complex assembled on the COL1A2-CAGA
probe included Smad 2/3, as demonstrated by antibody supershift-
ing. Furthermore, in vitro dephosphorylation of nuclear proteins
inhibited their binding to the probe, suggesting that phosphorylation
of one or more amino acid residues of Smad was important for
DNA-binding activity. These findings are consistent with a model
in which ligand-stimulated Smad phosphorylation plays a role in
activation of the intracellular TGF-β signaling cascade. A relatively
low level of CAGA-specific DNA-binding activity was detected
in untreated fibroblasts, and was rapidly induced by TGF-β. This
observation, taken together with the results of Smad mRNA
expression, and western immunoblotting studies, suggests that in
primary fibroblasts in culture, Smad genes are expressed, and their
products translocate into the nucleus and bind to target DNA
sequences independent of ligand. This may be the result of low-
level consitutive activation of the fibroblast TGF-β receptor caused
by endogenous TGF-β (Kawakami et al, 1998), or by TGF-β in
the media, and may account for the basal activity of the COL1A2
promoter. Stimulation of fibroblasts by TGF-β causes Smad
phosphorylation and increased Smad nuclear translocation, or the
recruitment of additional trans-acting factors such as Sp1, into the
Smad-containing DNA-binding complex, resulting in enhanced
transcription of target genes. The functional role of the putative
Smad-binding elements of COL1A2 in mediating the TGF-β
response of the gene, and the precise composition of the binding
complex, remain to be further delineated.
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